Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial.

Autor:	Royle KL; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK K.L.Royle@leeds.ac.uk., Coulson AB; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Ramasamy K; Radcliffe Department of Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Quezada S; Department of Haematology, UCL Cancer Institute, London, UK., Drayson M; Clinical Immunology Service, Institute of Immunology and Immunotherapy, Medical School, University of Birmingham, Birmingham, UK., Kaiser M; Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, UK., Owen R; HMDS, St James's University Hospital, Leeds, UK., Auner HW; Department of Immunology and Inflammation, Imperial College London, London, UK.; Langmuir Centre for Myeloma Research, Imperial College London, London, UK., Cook G; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK.; Leeds Cancer Centre, St James's University Hospital, Leeds, UK., Meads D; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Olivier C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Barnard L; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Lambkin R; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Paterson A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Insitute of Clinical Trials Research, University of Leeds, Leeds, UK., Dawkins B; Academic Unit of Health Economics, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK., Chapman M; Department of Haematology, University of Cambridge, Cambridge, UK., Pratt G; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK., Popat R; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., Jackson G; Northern Centre for Cancer Care, Freeman Hospital, Newcastle-Upon-Tyne, UK., Bygrave C; Department of Haematology, University Hospital of Wales, Cardiff, UK., Sive J; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK., de Tute R; HMDS, St James's University Hospital, Leeds, UK., Chantry A; Department of Haematology, Royal Hallamshire Hospital, Sheffield, UK., Parrish C; Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, UK., Cook M; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Bristol Myers Squibb, Boundry, Switzerland., Asher S; Department of Haematology, UCL Cancer Institute, London, UK., Yong K; Department of Haematology, UCL Cancer Institute, London, UK.
Jazyk:	angličtina
Zdroj:	BMJ open [BMJ Open] 2022 Nov 17; Vol. 12 (11), pp. e063037. Date of Electronic Publication: 2022 Nov 17.
DOI:	10.1136/bmjopen-2022-063037
Abstrakt:	Introduction: Multiple myeloma is a plasma cell malignancy that accounts for 1%-2% of newly diagnosed cancers.At diagnosis, approximately 20% of patients can be identified, using cytogenetics, to have inferior survival (high-risk). Additionally, standard-risk patients, with detectable disease (minimal residual disease (MRD)-positive) postautologus stem cell transplant (ASCT), fare worse compared with those who do not (MRD-negative). Research is required to determine whether a risk-adapted approach post-ASCT could further improve patient outcomes. Methods: RADAR is a UK, multicentre, risk-adapted, response-guided, open-label, randomised controlled trial for transplant-eligible newly diagnosed multiple myeloma patients, using combinations of lenalidomide (R), cyclophosphamide (Cy), bortezomib (Bor), dexamethasone (D) and isatuximab (Isa).Participants receive RCyBorD(x4) induction therapy, followed by high-dose melphalan and ASCT. Post-ASCT, there are three pathways as follows:A phase III discontinuation design to assess de-escalating therapy in standard-risk MRD-negative patients. Participants receive 12 cycles of Isa maintenance. Those who remain MRD-negative are randomised to either continue or stop treatment.A phase II/III multiarm multistage design to test treatment strategies for treatment escalation in standard-risk MRD-positive patients. Participants are randomised to either; R, RBorD(x4) +R, RIsa, or RBorIsaD(x4) + RIsa.A phase II design to assess the activity of intensive treatment strategies in high-risk patients. Participants are randomised to RBorD(x4) +R or RBorIsaD(x4) + RIsa.1400 participants will be registered to allow for 500, 450 and 172 participants in each pathway. Randomisations are equal and treatment is given until disease progression or intolerance. Ethics and Dissemination: Ethical approval was granted by the London-Central Research Ethics Committee (20/LO/0238) and capacity and capability confirmed by the appropriate local research and development department for each participating centre prior to opening recruitment. Participant informed consent is required before trial registration and reconfirmed post-ASCT. Results will be disseminated by conference presentations and peer-reviewed publications. Trial Registration Number: ISCRTN46841867. Competing Interests: Competing interests: ABC, KLR, DAC, AH, CO, LBai, LBar, AP and RL report grants and non-financial support from BMS/Celgene, grants and non-financial support from Merck Sharpe & Dohme, grants and non-financial support from Amgen, grants and non-financial support from Takeda, during the conduct of the trial. DAC also reports travel support from Celgene Corporation. KY, RDT, CB, GJ, GP, MC, BD, DM, GC, HA, KR,SA and AC have no conflicting interests to declare. MC declares, Bristol Myers Squibb- employee, Honoraria/travel support in the last 3 years from, Amgen, BMS/Celgene, Janssen, Takeda, Abbvie. CP declares BMS/Celgene Ad boards and speaker fees, Sanotif—Ad board, speaker fees, conference registration fees. JS reports Carrying out consultancy work (Advisory Board) for Sanofi. And an educational speaking engagement for Celgene/BMS RP declares; Honoraria—Jannsen, BMS, Abbvie, GSK. Consultancy: GSK, Janssen. Meeting support: Janssen, Takeda, BMS. RO declares- Janssen - advisory board, honoraria, Celegene— honoraria, Beigene - advisory board, honoraria, Astra Zeneca—honoraria. MK declares inter-relationships: AbbVie: consultancy; Amgen: honoraria; BMS/Celgene: consultancy, research funding (institution); GSK: consultancy; Janssen: consultancy, research funding (institution); Karyopharm: consultancy; Pfizer: consultancy; SeattleGenetics: consultancy; Takeda: consultancy; Sanofi: honoraria. MD reports owning stock in Abingdon Health. SQ is the founder and CSO of Achilles therapeutics a company developing T cell therapies for solid tumours. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu